Country: Malta
Language: English
Source: Medicines Authority
TIGECYCLINE
Mylan Ireland Limited Unit 35/36, Grange Parade, Baldoyle Industrial Estate, Dublin 13, Ireland
J01AA12
TIGECYCLINE 50 mg
POWDER FOR SOLUTION FOR INFUSION
TIGECYCLINE 50 mg
POM
ANTIBACTERIALS FOR SYSTEMIC USE
Authorised
2017-07-18
Page 1 of 7 PACKAGE LEAFLET: INFORMATION FOR THE USER TIGECYCLINE MYLAN 50 MG POWDER FOR SOLUTION FOR INFUSION Tigecycline READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU OR YOUR CHILD. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or nurse. - If you get any side effects, talk to your doctor, or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Tigecycline is and what it is used for 2. What you need to know before you receive Tigecycline 3. How Tigecycline is given 4. Possible side effects 5. How to store Tigecycline 6. Contents of the pack and other information 1. WHAT TIGECYCLINE IS AND WHAT IT IS USED FOR Tigecycline is an antibiotic of the glycylcycline group that works by stopping the growth of bacteria that cause infections. Your doctor has prescribed tigecycline because you or your child at least 8 years old has one of the following types of serious infections: • Complicated infection of the skin and soft tissues (the tissue below the skin), excluding diabetic foot infections. • Complicated infection in the abdomen Tigecycline is only used when your doctor thinks other antibiotics are not suitable. 2. WHAT YOU NEED TO KNOW BEFORE YOU RECEIVE TIGECYCLINE DO NOT USE TIGECYCLINE • If you are allergic to tigecycline, or any of the other ingredients of this medicine (listed in section 6). If you are allergic to tetracycline class antibiotics (e.g., minocycline, doxycycline, etc.), you may be allergic to tigecycline. WARNINGS AND PRECAUTIONS Talk to your doctor or nurse before receiving tigecycline: • If you have poor or slow wound healing. • If you are suffering from diarrhoea before you are given tigecycline. If you develop diarrhoea during or after your treatment, tell your doctor at once. Do not take any diarrhoea medicine without first checking with your doctor. • If you have or previously had a Read the complete document
Page 1 of 16 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Tigecycline Mylan 50 mg powder for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 50 mg of tigecycline. After reconstitution, 1 ml contains 10 mg of tigecycline. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for solution for infusion (powder for infusion). Orange to orange-red, lyophilized cake or powder, free of visible evidence of contamination. The pH of the reconstituted solution ranges between 4.0 and 6.0, and the osmolarity ranges between 240 – 320 mOsm/Kg depending on the reconstitution solvent. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Tigecycline is indicated in adults and in children from the age of eight years for the treatment of the following infections (see sections 4.4 and 5.1): • Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections (see section 4.4) • Complicated intra-abdominal infections (cIAI) Tigecycline should be used only in situations where other alternative antibiotics are not suitable (see sections 4.4, 4.8 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults _ The recommended dose is an initial dose of 100 mg followed by 50 mg every 12 hours for 5 to 14 days. _Children and adolescents (8 to 17 years of age) _ Children aged 8 to <12 years: 1.2 mg/kg of tigecycline every 12 hours intravenously to a maximum dose of 50 mg every 12 hours for 5 to 14 days. Adolescents aged 12 to <18 years: 50 mg of tigecycline every 12 hours for 5 to 14 days. The duration of therapy should be guided by the severity, site of the infection, and the patient’s clinical response. Page 2 of 16 _Elderly _ No dosage adjustment is necessary in elderly patients (see section 5.2). _ _ _Hepatic impairment _ No dosage adjustment is warranted in patients with mild to moderate hepatic impairment (Child Pugh A Read the complete document